(VIANEWS) – Today, the Innrs artificial intelligence algorithm suggests a high probability of discovering the approximate price for tomorrow of Novartis AG NVS, AbbVie ABBV and others.
Via News will regularly fact-check this AI algorithm that aims to consistently predict the next session price and next week’s trend of financial assets.
Innrs provides A.I.-based statistical tools to help investors make decisions. The table below shows the financial assets predicting price, ordered by the highest expected accuracy.
Innrs officials say this tool helps investors make better-informed decisions, supposedly used alongside other relevant financial information and the specific trader strategy.
In the next session, Via News will report the finding on the algorithm precision.
| Financial Asset | Accuracy | Close Price | Prediction |
|---|---|---|---|
| Novartis AG (NVS) | 94.35% | $82.33 | ⇧ $83.96 |
| AbbVie (ABBV) | 94.17% | $155.01 | ⇧ $157.44 |
| Take-Two Interactive Software (TTWO) | 93.49% | $115.32 | ⇧ $117.66 |
| NetEase (NTES) | 92.52% | $85.63 | ⇧ $88.13 |
| QuantumScape (QS) | 89.7% | $7.68 | ⇧ $7.82 |
| SK Telecom (SKM) | 88.9% | $20.85 | ⇧ $20.87 |
| Amerco (UHAL) | 88.64% | $56.74 | ⇩ $53.91 |
| Activision Blizzard (ATVI) | 88.55% | $79.81 | ⇧ $81.96 |
| Trip.com (TCOM) | 88.44% | $37.24 | ⇧ $37.5 |
| Match Group (MTCH) | 88.4% | $38.28 | ⇧ $39.75 |
| Petroleo Brasileiro (PBR) | 88.38% | $9.93 | ⇩ $9.79 |
| Pepsico (PEP) | 88.38% | $178.52 | ⇧ $183.96 |
| Franco (FNV) | 88.37% | $141.54 | ⇧ $146.2 |
| Electronic Arts (EA) | 88.3% | $114.13 | ⇧ $117.52 |
| Huazhu Group (HTHT) | 88.08% | $48.92 | ⇧ $50.15 |
| Eli Lilly and Company (LLY) | 88.02% | $333.51 | ⇧ $344.91 |
| Rollins (ROL) | 87.96% | $36.82 | ⇧ $37.55 |
| Ecopetrol S.A. (EC) | 87.7% | $10.16 | ⇩ $9.82 |
| Johnson & Johnson (JNJ) | 87.3% | $152.58 | ⇧ $158.14 |
| Ringcentral (RNG) | 86.41% | $28.58 | ⇩ $26.4 |
| Bank Nova Scotia Halifax (BNS) | 84.34% | $48.64 | ⇧ $49.18 |
| Intercontinental Exchange (ICE) | 84.09% | $98.88 | ⇧ $100.8 |
| Kodak (KODK) | 84.09% | $3.82 | ⇩ $3.44 |
| Biogen (BIIB) | 84.05% | $264.4 | ⇧ $269.28 |
| Zoetis (ZTS) | 83.98% | $163.89 | ⇧ $165.85 |
| argenx SE (ARGX) | 83.98% | $360.02 | ⇧ $366.37 |
| ONE Gas (OGS) | 83.98% | $77.21 | ⇧ $78.25 |
| Intuitive Surgical (ISRG) | 83.89% | $245.04 | ⇧ $251.9 |
| Baxter International (BAX) | 83.87% | $39.74 | ⇧ $40.22 |
| Regeneron Pharmaceuticals (REGN) | 83.83% | $756.88 | ⇧ $766.81 |
1. Novartis AG (NVS)
Shares of Novartis AG dropped 5.58% in from $87.2 to $82.33 at 19:21 EST on Wednesday, after four consecutive sessions in a row of gains. NYSE is sliding 0.35% to $14,933.06, after two sequential sessions in a row of gains.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4.8% and 2.6%, respectively.
Yearly Top and Bottom Value
Novartis AG’s stock is valued at $82.33 at 19:21 EST, way under its 52-week high of $94.26 and way above its 52-week low of $74.09.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.2%, now sitting on 51.83B for the twelve trailing months.
More news about Novartis AG.
2. AbbVie (ABBV)
Shares of AbbVie jumped 1.89% in from $152.13 to $155.01 at 19:21 EST on Wednesday, after two sequential sessions in a row of gains. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
More news about AbbVie.
3. Take-Two Interactive Software (TTWO)
Shares of Take-Two Interactive Software jumped 2.36% in from $112.66 to $115.32 at 19:21 EST on Wednesday, after four sequential sessions in a row of gains. NASDAQ is rising 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment solutions for consumers worldwide. The company offers its products under the Rockstar Games, 2K, Private Division, and T2 Mobile Games names. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead Redemption names; and offers episodes and content, as well as develops brands in other genres, including the LA Noire, Bully, and Manhunt franchises. The company also publishes various entertainment properties across various platforms and a range of genres, such as shooter, action, role-playing, strategy, sports, and family/casual entertainment under the BioShock, Mafia, Sid Meier's Civilization, XCOM series, and Borderlands. In addition, it publishes sports simulation titles comprising NBA 2K series, a basketball video game; the WWE 2K professional wrestling series; and PGA TOUR 2K. Further, the company offers Kerbal Space Program, OlliOlli World, and The Outer Worlds and Ancestors: the Humankind Odyssey under Private Division; and free-to-play mobile games, such as Dragon City, Monster Legends, Two Dots, and Top Eleven. Its products are designed for console gaming systems, including PlayStation 4 and PlayStation 5; Xbox One; the Nintendo's Switch; personal computers; and mobile comprising smartphones and tablets. The company provides its products through physical retail, digital download, online platforms, and cloud streaming services. Take-Two Interactive Software, Inc. was incorporated in 1993 and is based in New York, New York.
Volatility
Take-Two Interactive Software’s last week, last month’s, and last quarter’s current intraday variation average was 1.15%, 0.17%, and 1.58%.
Take-Two Interactive Software’s highest amplitude of average volatility was 1.15% (last week), 1.56% (last month), and 1.58% (last quarter).
More news about Take-Two Interactive Software.
4. NetEase (NTES)
Shares of NetEase rose 0.67% in from $85.06 to $85.63 at 19:21 EST on Wednesday, following the last session’s upward trend. NASDAQ is jumping 0.07% to $11,868.80, after two successive sessions in a row of gains.
NetEase, Inc. provides online services focusing on diverse content, community, communication, and commerce in the Peoples' Republic of China and internationally. The company operates in three segments: Online Game Services, Youdao, Cloud Music, and Innovative Businesses and Others. It develops and operates PC and mobile games, as well as offers games licensed from other game developers. The company's products and services include Youdao Dictionary, an online knowledge tool; Youdao Translation, a tool specifically designed to support translation needs of business and leisure travelers; U-Dictionary, an online dictionary and translation app; Youdao Kids' Dictionary, a smart and fun tool; smart devices, such as Youdao Dictionary Pen, Youdao Listening Pod, Youdao Smart Lamp, Youdao Pocket Translator, and Youdao Super Dictionary; online courses; interactive learning apps; enterprise services, such as Youdao Smart Learning Terminal, a device that automates paper-based homework processing and provides learning diagnosis through artificial intelligence technology at schools; and Youdao Smart Cloud, a cloud-based platform that allows third-party app developers, smart device brands and manufacturers to access advanced optical character recognition capabilities and neural machine translation engine. Its products and services also include NetEase Cloud Music, a music streaming platform; Yanxuan, an e-commerce platform, which sells private label products, including consumer electronics, food, apparel, homeware, kitchenware, and other general merchandise; NetEase Media, an internet media platform; NetEase Mail, an email service; NetEase CC Live streaming, a live streaming platform with a focus on game broadcasting; and NetEase Pay, a payment platform. The company was formerly known as NetEase.com, Inc. and changed its name to NetEase, Inc. in March 2012. NetEase, Inc. was founded in 1997 and is headquartered in Hangzhou, the People's Republic of China.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 95.52B for the twelve trailing months.
Sales Growth
NetEase’s sales growth is 10.3% for the present quarter and 11.4% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NetEase’s stock is considered to be oversold (<=20).
More news about NetEase.
5. QuantumScape (QS)
Shares of QuantumScape dropped by a staggering 27.08% in from $10.53 to $7.68 at 19:21 EST on Wednesday, after five successive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two sequential sessions in a row of gains.
QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Yearly Top and Bottom Value
QuantumScape’s stock is valued at $7.68 at 19:21 EST, way below its 52-week high of $22.21 and way higher than its 52-week low of $5.11.
Moving Average
QuantumScape’s worth is under its 50-day moving average of $8.14 and way under its 200-day moving average of $9.07.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, QuantumScape’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 37.5% and positive 4.8% for the next.
More news about QuantumScape.
6. SK Telecom (SKM)
Shares of SK Telecom jumped 8.42% in from $19.23 to $20.85 at 19:21 EST on Wednesday, after four successive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two successive sessions in a row of gains.
SK Telecom Co., Ltd. provides wireless telecommunication services in South Korea. The company operates through three segments: Cellular Services, Fixed-Line Telecommunications Services, and Other Businesses. The Cellular Services segment offers wireless voice and data transmission, Internet of Things solutions, platform, cloud, smart factory solutions, subscription, and metaverse platform-based services, as well as sells wireless devices. The Fixed-Line Telecommunications Services segment provides fixed-line telephone services; broadband Internet services; media platform services, such as Internet protocol TV and cable TV; and business communications services. The Other Businesses segment offers television shopping services under the T-commerce brand, as well as portal services. In addition, it provides call center management, base station maintenance, information gathering and consulting, system software development and supply, quantum information and communications, data base and internet website, and digital contents sourcing services; manufactures and sells e-book; sells contents and mastering quality sound album; sells and trades in anti-theft and surveillance devices; and operates information and communications facilities. As of December 31, 2021, the company had 3.6 million fixed-line telephone and 31.9 million wireless subscribers. SK Telecom Company Limited was incorporated in 1984 and is headquartered in Seoul, South Korea.
More news about SK Telecom.
7. Amerco (UHAL)
Shares of Amerco fell by a staggering 12.55% in from $64.88 to $56.74 at 19:21 EST on Wednesday, following the last session’s upward trend. NASDAQ is rising 0.07% to $11,868.80, after two successive sessions in a row of gains.
U-Haul Holding Company operates as a do-it-yourself moving and storage operator for household and commercial goods in the United States and Canada. The company's Moving and Storage segment rents trucks, trailers, portable moving and storage units, specialty rental items, and self-storage spaces primarily to the household movers; and sells moving supplies, towing accessories, and propane. It also provides uhaul.com, an online marketplace that connects consumers to independent Moving Help service providers and independent self-storage affiliates; auto transport and tow dolly options to transport vehicles; and specialty boxes for dishes, computers, flat screen television, and sensitive electronic equipment, as well as tapes, security locks, and packing supplies. This segment rents its products and services through a network of approximately 2,100 company operated retail moving stores and 21,100 independent U-Haul dealers. As of March 31, 2022, it had a rental fleet of approximately 186,000 trucks, 128,000 trailers, and 46,000 towing devices; and 1,844 self-storage locations with approximately 876,000 rentable storage units. The company's Property and Casualty Insurance segment offers loss adjusting and claims handling services. It also provides moving and storage protection packages, such as Safemove and Safetow packages, which offer moving and towing customers with a damage waiver, cargo protection, and medical and life insurance coverage; Safestor that protects storage customers from loss on their goods in storage; Safestor Mobile, which protects customers stored belongings; and Safemove Plus, which provides rental customers with a layer of primary liability protection. The company's Life Insurance segment provides life and health insurance products primarily to the senior market through the direct writing and reinsuring of life insurance, medicare supplement, and annuity policies. The company was formerly known as AMERCO. U-Haul Holding Company was founded in 1945 and is based in Reno, Nevada.
More news about Amerco.
8. Activision Blizzard (ATVI)
Shares of Activision Blizzard rose 3.65% in from $77 to $79.81 at 19:21 EST on Wednesday, after two successive sessions in a row of gains. NASDAQ is jumping 0.07% to $11,868.80, after two sequential sessions in a row of gains.
Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company is headquartered in Santa Monica, California.
Yearly Top and Bottom Value
Activision Blizzard’s stock is valued at $79.81 at 19:21 EST, below its 52-week high of $81.50 and way higher than its 52-week low of $70.94.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 36.8% and 85.1%, respectively.
Moving Average
Activision Blizzard’s value is higher than its 50-day moving average of $76.72 and above its 200-day moving average of $76.45.
More news about Activision Blizzard.
9. Trip.com (TCOM)
Shares of Trip.com jumped 2.22% in from $36.43 to $37.24 at 19:21 EST on Wednesday, after two consecutive sessions in a row of gains. NASDAQ is rising 0.07% to $11,868.80, after two sequential sessions in a row of gains.
Trip.com Group Limited operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours and in-destination, corporate travel management, and other travel-related services in China and internationally. The company acts as an agent for hotel-related transactions and selling air tickets, as well as provides train, long-distance bus, and ferry tickets; travel insurance products, such as flight delay, air accident, and baggage loss coverage; and air-ticket delivery, online check-in and seat selection, express security screening, real-time flight status tracker, and airport VIP lounge services. It also provides independent leisure travelers bundled packaged-tour products comprising group, semi-group, and customized and packaged tours with various transportation arrangements, such as air, cruise, bus, and car rental services. In addition, the company offers integrated transportation and accommodation services; destination transportation and ticket, activity, insurance, visa, and tour guide services; user support, supplier management, and customer relationship management services; and in-destination products and services. Further, it provides its corporate clients with business visit, incentive trip, meeting and conference, travel data collection and analysis, industry benchmark, cost saving analysis, and travel management solutions; and Corporate Travel Management System, an online platform that integrates information management, online booking and authorization, online enquiry, and travel reporting systems. Additionally, the company offers online advertising and financial services. It operates under the Ctrip, Qunar, Trip.com, and Skyscanner brands. The company was formerly known as Ctrip.com International, Ltd. and changed its name to Trip.com Group Limited in October 2019. Trip.com Group Limited was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.
Sales Growth
Trip.com’s sales growth is 9.9% for the ongoing quarter and 36.4% for the next.
Moving Average
Trip.com’s worth is higher than its 50-day moving average of $37.11 and way higher than its 200-day moving average of $29.15.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 142.9% and positive 500% for the next.
Yearly Top and Bottom Value
Trip.com’s stock is valued at $37.24 at 19:21 EST, below its 52-week high of $40.17 and way above its 52-week low of $14.29.
More news about Trip.com.
10. Match Group (MTCH)
Shares of Match Group dropped by a staggering 11.02% in from $43.02 to $38.28 at 19:21 EST on Wednesday, after five successive sessions in a row of gains. NASDAQ is rising 0.07% to $11,868.80, after two successive sessions in a row of gains.
Match Group, Inc. provides dating products worldwide. The company's portfolio of brands includes Tinder, Match, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and OurTime, as well as a various other brands. The company was incorporated in 1986 and is based in Dallas, Texas.
Sales Growth
Match Group’s sales growth is negative 0.5% for the current quarter and 4% for the next.
Moving Average
Match Group’s value is way below its 50-day moving average of $45.11 and way under its 200-day moving average of $54.92.
More news about Match Group.
11. Petroleo Brasileiro (PBR)
Shares of Petroleo Brasileiro dropped by a staggering 13.6% in from $11.49 to $9.93 at 19:21 EST on Wednesday, after two consecutive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two successive sessions in a row of gains.
Petróleo Brasileiro S.A. – Petrobras explores for, produces, and sells oil and gas in Brazil and internationally. The company operates through Exploration and Production; Refining, Transportation and Marketing; Gas and Power; and Corporate and Other Businesses segments. It engages in prospecting, drilling, refining, processing, trading, and transporting crude oil from producing onshore and offshore oil fields, and shale or other rocks, as well as oil products, natural gas, and other liquid hydrocarbons. The Exploration and Production segment explores, develops, and produces crude oil, natural gas liquids, and natural gas primarily for supplies to the domestic refineries. The Refining, Transportation and Marketing segment engages in the refining, logistics, transport, marketing, and trading of crude oil and oil products; exportation of ethanol; and extraction and processing of shale, as well as holding interests in petrochemical companies. The Gas and Power segment is involved in the logistic and trading of natural gas and electricity; transportation and trading of LNG; generation of electricity through thermoelectric power plants; holding interests in transportation and distribution of natural gas; and fertilizer production and natural gas processing business. The Corporate and Other Businesses segment produces biodiesel and its co-products, and ethanol; and distributes oil products. Petróleo Brasileiro S.A. – Petrobras was incorporated in 1953 and is headquartered in Rio de Janeiro, Brazil.
More news about Petroleo Brasileiro.
12. Pepsico (PEP)
Shares of Pepsico jumped 1.18% in from $176.44 to $178.52 at 19:21 EST on Wednesday, after three successive sessions in a row of gains. NASDAQ is jumping 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.
Moving Average
Pepsico’s value is higher than its 50-day moving average of $174.34 and higher than its 200-day moving average of $173.55.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 83.64B for the twelve trailing months.
Volatility
Pepsico’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.01%, a negative 0.09%, and a positive 0.71%.
Pepsico’s highest amplitude of average volatility was 0.56% (last week), 0.63% (last month), and 0.71% (last quarter).
More news about Pepsico.
13. Franco (FNV)
Shares of Franco rose 8.59% in from $130.34 to $141.54 at 19:21 EST on Wednesday, after two consecutive sessions in a row of losses. NYSE is falling 0.35% to $14,933.06, after two successive sessions in a row of gains.
Franco-Nevada Corporation operates as a gold-focused royalty and streaming company in Latin America, the United States, Canada, and internationally. It operates in two segments, Mining and Energy. The company manages its portfolio with a focus on precious metals, such as gold, silver, and platinum group metals; and energy comprising oil, gas, and natural gas liquids. The company was founded in 1983 and is headquartered in Toronto, Canada.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.9%, now sitting on 1.32B for the twelve trailing months.
More news about Franco.
14. Electronic Arts (EA)
Shares of Electronic Arts rose 1.85% in from $112.06 to $114.13 at 19:21 EST on Wednesday, after two successive sessions in a row of gains. NASDAQ is jumping 0.07% to $11,868.80, after two sequential sessions in a row of gains.
Electronic Arts Inc. develops, markets, publishes, and distributes games, content, and services for game consoles, PCs, mobile phones, and tablets worldwide. It develops and publishes games and services across various genres, such as sports, racing, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Need for Speed, and license games from others, including FIFA, Madden NFL, UFC, and Star Wars brands. The company licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution and retail channels, as well as directly to mass market retailers, specialty stores, and distribution arrangements. Electronic Arts Inc. was incorporated in 1982 and is headquartered in Redwood City, California.
Yearly Top and Bottom Value
Electronic Arts’s stock is valued at $114.13 at 19:21 EST, way below its 52-week high of $142.79 and higher than its 52-week low of $108.92.
Sales Growth
Electronic Arts’s sales growth is negative 1% for the ongoing quarter and 20.9% for the next.
More news about Electronic Arts.
15. Huazhu Group (HTHT)
Shares of Huazhu Group slid 1.17% in from $49.5 to $48.92 at 19:21 EST on Wednesday, after two sequential sessions in a row of gains. NASDAQ is jumping 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
H World Group Limited, together with its subsidiaries, develops leased and owned, manachised, and franchised hotels primarily in the People's Republic of China. The company operates hotels under its own brands, such as HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, Ibis Hotel, JI Hotel, Orange Hotel, Starway Hotel, Ibis Styles Hotel, CitiGO Hotel, Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, MAXX by Steigenberger, Jaz in the City, Grand Mercure, Steigenberger Icon, and Song Hotels. The company was formerly known as Huazhu Group Limited and changed its name to H World Group Limited in June 2022. H World Group Limited was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.
Volatility
Huazhu Group’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.15%, a negative 0.75%, and a positive 2.32%.
Huazhu Group’s highest amplitude of average volatility was 1.85% (last week), 2.71% (last month), and 2.32% (last quarter).
Yearly Top and Bottom Value
Huazhu Group’s stock is valued at $48.92 at 19:21 EST, below its 52-week high of $53.52 and way higher than its 52-week low of $24.38.
Moving Average
Huazhu Group’s worth is higher than its 50-day moving average of $48.65 and way above its 200-day moving average of $39.59.
More news about Huazhu Group.
16. Eli Lilly and Company (LLY)
Shares of Eli Lilly and Company rose 1.77% in from $327.71 to $333.51 at 19:21 EST on Wednesday, following the last session’s downward trend. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 33.2% and positive 49.6% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Eli Lilly and Company’s stock is considered to be oversold (<=20).
Moving Average
Eli Lilly and Company’s value is below its 50-day moving average of $336.51 and above its 200-day moving average of $333.00.
Volatility
Eli Lilly and Company’s last week, last month’s, and last quarter’s current intraday variation average was 0.42%, 0.05%, and 1.15%.
Eli Lilly and Company’s highest amplitude of average volatility was 0.49% (last week), 1.19% (last month), and 1.15% (last quarter).
More news about Eli Lilly and Company.
17. Rollins (ROL)
Shares of Rollins rose 4.22% in from $35.33 to $36.82 at 19:21 EST on Wednesday, after four successive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two successive sessions in a row of gains.
Rollins, Inc., through its subsidiaries, provides pest and wildlife control services to residential and commercial customers in the United States and internationally. The company offers pest control services to residential properties protecting from common pests, including rodents, insects, and wildlife. It also provides workplace pest control solutions for customers across various end markets, such as healthcare, foodservice, and logistics. In addition, the company offers traditional and baiting termite protection, as well as ancillary services. It serves clients directly, as well as through franchisee operations. Rollins, Inc. was incorporated in 1948 and is headquartered in Atlanta, Georgia.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 2.63B for the twelve trailing months.
More news about Rollins.
18. Ecopetrol S.A. (EC)
Shares of Ecopetrol S.A. slid 2.66% in from $10.44 to $10.16 at 19:21 EST on Wednesday, after two successive sessions in a row of gains. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
Ecopetrol S.A. operates as an integrated energy company. The company operates through four segments: Exploration and Production; Transport and Logistics; Refining, Petrochemical and Biofuels; and Electric Power Transmission and Toll Roads Concessions. It engages in the exploration and production of oil and gas; transportation of crude oil, motor fuels, fuel oil, and other refined products, including diesel, jet, and biofuels; processing and refining crude oil; distribution of natural gas and LPG; sale of refined and petrochemical products; supplying of electric power transmission services; design, development, construction, operation, and maintenance of road and energy infrastructure projects; and supplying of information technology and telecommunications services. As of December 31, 2021, the company had approximately 9,127 kilometers of crude oil and multi-purpose pipelines. It also produces and commercializes polypropylene resins and compounds, and masterbatches; and offers industrial service sales to customers and specialized management services. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, South America, and internationally. The company was formerly known as Empresa Colombiana de Petróleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was incorporated in 1948 and is based in Bogotá, Colombia.
Sales Growth
Ecopetrol S.A.’s sales growth is 59.4% for the ongoing quarter and 26.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 130.6% and 81.3%, respectively.
Moving Average
Ecopetrol S.A.’s value is under its 50-day moving average of $11.04 and below its 200-day moving average of $10.85.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ecopetrol S.A.’s stock is considered to be overbought (>=80).
More news about Ecopetrol S.A..
19. Johnson & Johnson (JNJ)
Shares of Johnson & Johnson slid 3.81% in from $158.62 to $152.58 at 19:21 EST on Wednesday, following the last session’s downward trend. NYSE is dropping 0.35% to $14,933.06, after two consecutive sessions in a row of gains.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.4%, now sitting on 94.94B for the twelve trailing months.
Sales Growth
Johnson & Johnson’s sales growth is 1.1% for the ongoing quarter and 2.1% for the next.
Volatility
Johnson & Johnson’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.10%, a negative 0.20%, and a positive 0.75%.
Johnson & Johnson’s highest amplitude of average volatility was 0.76% (last week), 0.77% (last month), and 0.75% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 5.6% and positive 0.8% for the next.
More news about Johnson & Johnson.
20. Ringcentral (RNG)
Shares of Ringcentral slid by a staggering 24.56% in from $37.88 to $28.58 at 19:21 EST on Wednesday, after two successive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two consecutive sessions in a row of gains.
RingCentral, Inc. provides software-as-a-service solutions that enable businesses to communicate, collaborate, and connect in North America. The company offers business cloud communications and contact center solutions based on its Message Video Phone? platform. Its products include RingCentral Office that provides communication and collaboration across various modes, including high-definition voice, video, SMS, messaging and collaboration, conferencing, online meetings, and fax; RingCentral Contact Center, a collaborative contact center solution that delivers omni-channel; and RingCentral Engage Digital, a digital customer engagement platform that allows enterprises to interact with their customers. The company's products also comprise RingCentral Engage Voice, a cloud-based outbound/blended customer engagement platform for midsize and enterprise companies; RingCentral Video, a video meeting service which includes our RCV video and team messaging capabilities and offers video and audio conferencing, file sharing, contact, task, and calendar management. In addition, it offers RingCentral Professional, a cloud based virtual telephone service that provides inbound call answering and management services for professionals; and RingCentral Fax that provides online fax capabilities. The company serves a range of industries, including financial services, education, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, and state and local government, as well as others. It sells its products through a network of direct sales representatives, as well as sales agents, resellers, and channel partners. RingCentral, Inc. has strategic partnerships with Alcatel-Lucent Enterprise; and Vodafone Business. The company was incorporated in 1999 and is headquartered in Belmont, California.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ringcentral’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
Ringcentral’s stock is valued at $28.58 at 19:21 EST, way under its 52-week high of $129.72 and higher than its 52-week low of $28.00.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 51.3% and 61.5%, respectively.
Volatility
Ringcentral’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.71%, a negative 1.90%, and a positive 3.80%.
Ringcentral’s highest amplitude of average volatility was 4.71% (last week), 3.50% (last month), and 3.80% (last quarter).
More news about Ringcentral.
21. Bank Nova Scotia Halifax (BNS)
Shares of Bank Nova Scotia Halifax dropped 9.23% in from $53.59 to $48.64 at 19:21 EST on Wednesday, after four consecutive sessions in a row of gains. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
The Bank of Nova Scotia engages in the provision of various banking products and services in Canada, the United States, Mexico, Peru, Chile, Colombia, the Caribbean and Central America, and internationally. It operates through four segments: Canadian Banking, International Banking, Global Wealth Management, and Global Banking and Markets. The company offers financial advice and solutions, and day-to-day banking products, including debit and credit cards, chequing and saving accounts, investments, mortgages, loans, and insurance to individuals; and business banking solutions comprising lending, deposit, cash management, and trade finance solutions to small, medium, and large businesses, including automotive financing solutions to dealers and their customers. It also provides wealth management advice and solutions, including online brokerage, mobile investment, full-service brokerage, trust, private banking, and private investment counsel services; and retail mutual funds, exchange traded funds, liquid alternative funds, and institutional funds. In addition, the company offers international banking services for retail, corporate, and commercial customers; and lending and transaction, investment banking advisory, and capital markets access services to corporate customers. Further, it provides online, mobile, and telephone banking services. The company operates a network of 941 branches and approximately 3,725 automated banking machines in Canada; and approximately 1,200 branches and a network of contact and support center internationally. The Bank of Nova Scotia was founded in 1832 and is headquartered in Toronto, Canada.
Yearly Top and Bottom Value
Bank Nova Scotia Halifax’s stock is valued at $48.64 at 19:21 EST, way below its 52-week high of $74.82 and above its 52-week low of $45.26.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Bank Nova Scotia Halifax’s stock is considered to be oversold (<=20).
More news about Bank Nova Scotia Halifax.
22. Intercontinental Exchange (ICE)
Shares of Intercontinental Exchange dropped 5.35% in from $104.47 to $98.88 at 19:21 EST on Wednesday, after two successive sessions in a row of gains. NYSE is dropping 0.35% to $14,933.06, after two successive sessions in a row of gains.
Intercontinental Exchange, Inc., together with its subsidiaries, engages in the provision of market infrastructure, data services, and technology solutions for financial institutions, corporations, and government entities in the United States, the United Kingdom, the European Union, Singapore, India, Abu Dhabi, Israel, and Canada. It operates through three segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The company operates regulated marketplaces for listing, trading, and clearing an array of derivatives contracts and financial securities, such as commodities, interest rates, foreign exchange, and equities, as well as corporate and exchange-traded funds; and trading venues, including regulated exchanges and clearing houses. It also offers energy, agricultural and metals, and financial futures and options; and cash equities and equity options, and over-the-counter and other markets, as well as listings and data and connectivity services. In addition, the company provides fixed income data and analytic, fixed income execution, CDS clearing, and other multi-asset class data and network services. Further, it offers proprietary and comprehensive mortgage origination platform, which serves residential mortgage loans; closing solutions that provides customers connectivity to the mortgage supply chain and facilitates the secure exchange of information; data and analytics services; and Data as a Service for lenders to access data and origination information. Intercontinental Exchange, Inc. was founded in 2000 and is headquartered in Atlanta, Georgia.
Moving Average
Intercontinental Exchange’s worth is below its 50-day moving average of $105.09 and under its 200-day moving average of $101.00.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.9%, now sitting on 7.29B for the twelve trailing months.
Yearly Top and Bottom Value
Intercontinental Exchange’s stock is valued at $98.88 at 19:21 EST, way under its 52-week high of $137.21 and way above its 52-week low of $88.60.
Volatility
Intercontinental Exchange’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.17%, a negative 0.43%, and a positive 1.18%.
Intercontinental Exchange’s highest amplitude of average volatility was 1.71% (last week), 1.73% (last month), and 1.18% (last quarter).
More news about Intercontinental Exchange.
23. Kodak (KODK)
Shares of Kodak rose 7.91% in from $3.54 to $3.82 at 19:21 EST on Wednesday, following the last session’s upward trend. NYSE is falling 0.35% to $14,933.06, after two successive sessions in a row of gains.
Eastman Kodak Company provides hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment offers digital offset plate and computer-to-plate imaging solutions to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The Digital Printing segment provides electrophotographic printing solutions, such as The ASCEND and NEXFINITY printers; prosper products, including the PROSPER 6000 Press, PROSPER Writing Systems, PROSPER press systems, and PROSPER components; versamark products; and PRINERGY workflow production software. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, and advanced materials and functional printing businesses. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company engages in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.
Yearly Top and Bottom Value
Kodak’s stock is valued at $3.82 at 19:21 EST, way below its 52-week high of $7.50 and way higher than its 52-week low of $2.78.
Volatility
Kodak’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.41%, a negative 0.27%, and a positive 3.17%.
Kodak’s highest amplitude of average volatility was 4.26% (last week), 3.23% (last month), and 3.17% (last quarter).
More news about Kodak.
24. Biogen (BIIB)
Shares of Biogen slid 3.06% in from $272.75 to $264.40 at 19:21 EST on Wednesday, following the last session’s downward trend. NASDAQ is jumping 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Volatility
Biogen’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.36%, a negative 0.20%, and a positive 1.16%.
Biogen’s highest amplitude of average volatility was 1.09% (last week), 1.01% (last month), and 1.16% (last quarter).
More news about Biogen.
25. Zoetis (ZTS)
Shares of Zoetis fell 3.61% in from $170.03 to $163.89 at 19:21 EST on Wednesday, after four sequential sessions in a row of gains. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
More news about Zoetis.
26. argenx SE (ARGX)
Shares of argenx SE slid 2.03% in from $367.48 to $360.02 at 19:21 EST on Wednesday, following the last session’s downward trend. NASDAQ is jumping 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1961.8%, now sitting on 285.68M for the twelve trailing months.
Moving Average
argenx SE’s value is below its 50-day moving average of $371.07 and under its 200-day moving average of $368.91.
Yearly Top and Bottom Value
argenx SE’s stock is valued at $360.02 at 19:21 EST, way below its 52-week high of $407.93 and way higher than its 52-week low of $267.35.
More news about argenx SE.
27. ONE Gas (OGS)
Shares of ONE Gas fell 3.79% in from $80.25 to $77.21 at 19:21 EST on Wednesday, after two successive sessions in a row of losses. NYSE is falling 0.35% to $14,933.06, after two consecutive sessions in a row of gains.
ONE Gas, Inc., together with its subsidiaries, operates as a regulated natural gas distribution utility company in the United States. The company operates through three divisions: Oklahoma Natural Gas, Kansas Gas Service, and Texas Gas Service. It provides natural gas distribution services to 2.2 million customers in three states. It serves residential, commercial, and transportation customers. As of December 31, 2021, it operated approximately 41,600 miles of distribution mains; and 2,400 miles of transmission pipelines, as well as had 51.4 billion cubic feet of natural gas storage capacity. ONE Gas, Inc. was founded in 1906 and is headquartered in Tulsa, Oklahoma.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONE Gas’s stock is considered to be oversold (<=20).
Sales Growth
ONE Gas’s sales growth is negative 27.5% for the present quarter and negative 8% for the next.
Volatility
ONE Gas’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.03%, a negative 0.12%, and a positive 1.30%.
ONE Gas’s highest amplitude of average volatility was 1.17% (last week), 1.42% (last month), and 1.30% (last quarter).
Moving Average
ONE Gas’s value is under its 50-day moving average of $79.66 and under its 200-day moving average of $79.39.
More news about ONE Gas.
28. Intuitive Surgical (ISRG)
Shares of Intuitive Surgical jumped 4.93% in from $233.53 to $245.04 at 19:21 EST on Wednesday, after two sequential sessions in a row of gains. NASDAQ is jumping 0.07% to $11,868.80, after two consecutive sessions in a row of gains.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Sales Growth
Intuitive Surgical’s sales growth is 6.8% for the present quarter and 11.7% for the next.
Yearly Top and Bottom Value
Intuitive Surgical’s stock is valued at $245.04 at 19:21 EST, way below its 52-week high of $308.97 and way higher than its 52-week low of $180.07.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Intuitive Surgical’s stock is considered to be oversold (<=20).
More news about Intuitive Surgical.
29. Baxter International (BAX)
Shares of Baxter International dropped 2.57% in from $40.79 to $39.74 at 19:21 EST on Wednesday, after two sequential sessions in a row of gains. NYSE is falling 0.35% to $14,933.06, after two sequential sessions in a row of gains.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Moving Average
Baxter International’s worth is below its 50-day moving average of $42.59 and way under its 200-day moving average of $54.55.
Yearly Top and Bottom Value
Baxter International’s stock is valued at $39.74 at 19:21 EST, way below its 52-week high of $80.72 and higher than its 52-week low of $37.35.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 28% and a negative 13.8%, respectively.
More news about Baxter International.
30. Regeneron Pharmaceuticals (REGN)
Shares of Regeneron Pharmaceuticals rose 1.26% in from $747.46 to $756.88 at 19:21 EST on Wednesday, after two sequential sessions in a row of gains. NASDAQ is rising 0.07% to $11,868.80, after two sequential sessions in a row of gains.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Revenue Growth
Year-on-year quarterly revenue growth declined by 31%, now sitting on 12.17B for the twelve trailing months.
More news about Regeneron Pharmaceuticals.
